Free Trial
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel
OTCMKTS:NWBO

Northwest Biotherapeutics Q2 2024 Earnings Report

Northwest Biotherapeutics logo
$0.19 0.00 (-0.42%)
As of 03:59 PM Eastern
ProfileEarnings History

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$0.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Northwest Biotherapeutics Announcement Details

Quarter
Q2 2024
Date
8/9/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Northwest Biotherapeutics' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-appoints-dr-annalisa-jenkins-as-strategic-adviser-to-advance-dendritic-cell-cancer-vaccine-platform-302759157.html
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
April 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-establishment-of-the-companys-own-dedicated-leukapheresis-clinic-302748049.html
Sell these "safe" blue chips immediately
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
June 16 at 1:00 AM  |  Chaikin Analytics (Ad)
Northwest Biotherapeutics expands authorized common stock capacity
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/northwest-biotherapeutics-expands-authorized-common-stock-capacity/ar-AA1Tu2yI
Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK ...
November 22, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/67037333-northwest-biotherapeutics-inc-northwest-biotherapeutics-announces-that-construction-activities-are-under-way-for-the-first-grade-c-manufacturing-su-008.htm
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
November 20, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-construction-activities-are-under-way-for-the-first-grade-c-manufacturing-suite-in-the-sawston-uk-facility-302622243.html
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO) is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.

View Northwest Biotherapeutics Profile
Earnings Tools